All In Biotech

Drug Trial Radar · NCT00855465

A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.

Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of Oral BAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

Last checked: Nov 20, 2026Latest source record: Nov 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 262 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

262

Actual

Start

Feb 23, 2009

Primary completion

Jun 27, 2012

Study completion Jun 27, 2012

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
Mar 4, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of the study is to assess the efficacy and safety of different doses of BAY63-2521, given orally for 16 weeks, in patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH).

Conditions

  • Pulmonary Hypertension

Interventions

  • Riociguat (Adempas, BAY63-2521)Drug

    BAY63-2521: 1 mg tid - 2,5 mg tid orally for 16 weeks.

  • PlaceboDrug

    Matching Placebo tid orally for 16 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 6 Minutes Walking Distance (6MWD) - Change From Baseline to Week 16Time frame: Baseline and week 16

Locations

89 sites in 26 countries. Site status is shown where the registry gives one.

  • Site not named

    La Jolla, California

  • Site not named

    Sacramento, California

  • Site not named

    Miami, Florida

  • Site not named

    Iowa City, Iowa

  • Site not named

    Baltimore, Maryland

  • Site not named

    Boston, Massachusetts

  • Site not named

    Cleveland, Ohio

  • Site not named

    Columbus, Ohio

  • Site not named

    Dallas, Texas

  • Site not named

    Corrientes, Argentina

  • Site not named

    Prahran, Victoria, Australia

  • Site not named

    Innsbruck, Austria

  • Site not named

    Vienna, Austria

  • Site not named

    Bruxelles - Brussel, Belgium

  • Site not named

    Leuven, Belgium

  • Site not named

    Rio de Janeiro, Brazil

  • Site not named

    Porto Alegre, Rio Grande do Sul, Brazil

  • Site not named

    São Paulo, São Paulo, Brazil

  • Site not named

    Calgary, Alberta, Canada

  • Site not named

    London, Ontario, Canada

  • Site not named

    Ottawa, Ontario, Canada

  • Site not named

    Toronto, Ontario, Canada

  • Site not named

    Montreal, Quebec, Canada

  • Site not named

    Beijing, China

  • Site not named

    Beijing, China

  • Site not named

    Beijing, China

  • Site not named

    Shanghai, China

  • Site not named

    Qingdao, Shandong, China

  • Vseobecna fakultni nemocnice

    Prague, Czechia

  • Site not named

    Aarhus N, Denmark

  • Site not named

    Brest, France

  • Site not named

    Caen, France

  • Hopital Antoine Beclere

    Clamart, France

  • Site not named

    Lille, France

  • Site not named

    Nice, France

  • Site not named

    Pessac, France

  • Site not named

    Rouen, France

  • Site not named

    Vandœuvre-lès-Nancy, France

  • Site not named

    Hamburg, Germany

  • Site not named

    Heidelberg, Baden-Wurttemberg, Germany

Showing 40 of 89 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.